Arecor and JDRF announce successful pre-clinical development of diabetes treatment

Arecor’s proprietary insulin product to progress into human scientific trials in 2018.

Cambridge (UK), New York (USA),  fourth January 2018:  Arecor Limited,  a pacesetter in growing superior biopharmaceuticals via the appliance of an revolutionary formulation know-how platform, and JDRF, the main world organisation funding sort 1 diabetes analysis, are happy to announce the successful completion of their partnered programme and the pre-clinical development of an ultra-concentrated, rapid-acting insulin product (the product) for the considerably enhanced treatment of insulin-requiring diabetes, notably sort 1 diabetes.  

The product, which is scheduled to progress right into a first-in-human scientific research in folks with sort 1 diabetes in 2018, is a big step towards enabling miniaturization of next-generation insulin supply applied sciences which are promising to rework the life of folks with diabetes. The product may also supply superior treatment and high quality of life for folks requiring giant doses of insulin to handle their situation.

More particularly, the product will considerably enhance the treatment of sufferers requiring greater than 200 Units of insulin per day. Development of an ultra-concentrated insulin product, succesful of delivering as much as 1,000 Units/mL, was hitherto a substantial scientific problem, however is one which has now been efficiently addressed throughout the development programme, by making use of Arecor’s proprietary formulation know-how, Arestat™, to present off-patent fast performing insulin analogues at concentrations of as much as 1,000 Units/mL.

The product has been proven to display an analogous fast onset of motion, compared to the at the moment marketed low-concentration analogues.  The product has additionally demonstrated wonderful stability, which is all the time a pre-requisite for any commercially viable product.   Indeed, throughout the programme, a quantity of appreciable challenges related to growing insulin focus, akin to poor stability and the sluggish onset of insulin motion, have been overcome utilizing the Arestat™ know-how.  The know-how has moreover delivered wonderful fast pharmacokinetic and pharmacodynamic profiles in validated animal fashions, compared to at the moment marketed, competitor rapid-acting merchandise.

Sanjoy Dutta, JDRF commented: “We are pleased at the progress being delivered as a result of JDRF’s partnership with Arecor, as we seek to improve the delivery and control of insulin,” stated Sanjoy Dutta, JDRF Assistant Vice President, Research. “People with type 1 diabetes are looking forward to smaller devices that can help them maintain glucose control safely and conveniently. Achieving miniaturized technologies, and therefore an improved quality of life, will require ultra-concentrated insulins such as the one being developed through this research.”

Arecor’s CEO, Sarah Howell, commented: “The successful development of the ultra-concentrated rapid acting insulin is a very important milestone in Arecor’s mission to develop superior proprietary products that will significantly improve the treatment options and ultimately the quality of life of people living with diabetes. Having already succeeded in developing a pre-clinical proof-of-concept insulin with ultra-fast onset, the ultra-concentrated rapid acting insulin is another key product within our diabetes portfolio. The support from JDRF has been invaluable and we look forward to continuing to build this fruitful partnership to deliver our shared common future objectives – namely to deliver substantially improved treatment options for people living with diabetes”.



About diabetes

Diabetes mellitus, usually shortened to “diabetes”, is a continual situation that impacts the physique’s potential to regulate blood sugar degree and use vitality from meals. In a wholesome physique, carbohydrates from vitamin are damaged right down to glucose, which in flip offers vitality for the cells. This course of is managed by a hormone referred to as insulin. Diabetes is because of the lack of ability of the physique to provide sufficient insulin (Type 1 diabetes) or to make use of it correctly (Type 2 diabetes). If left untreated, diabetes results in critical well being issues, together with coronary heart illness, kidney failure, nerve harm or blindness. The incidence of diabetes is growing very quickly, placing a big monetary burden on healthcare methods all over the world. Worldwide, there are at the moment about 415 million folks with diabetes, anticipated to develop to about 642 million diabetics by 2040 (International Diabetes Federation, Diabetes Atlas, 2015).   

About insulin treatment

The key aim of diabetes treatment is to maintain blood glucose ranges in a wholesome vary in order to cut back the danger of organ harm and different issues that outcome from continual hyperglycaemia.  Insulin is a vital half of the diabetes treatment, notably Type 1 diabetes. To guarantee simpler treatment a spread of insulin analogues have been developed, together with analogues that act very quickly to make sure an efficient discount of blood glucose after meals.  Different supply strategies for insulin have additionally been developed over time to make sure comfort for the sufferers and the absolute best therapeutic outcomes. Traditional syringes have been progressively changed by extra handy insulin pens that use pre-filled cartridges and a nice needle and insulin pumps that dispense insulin via versatile tubing to a catheter below the pores and skin of the abdomen are more and more used. New technology pumps are at the moment being developed to make sure higher comfort by extra discrete dimension and design in addition to their helpful connectivity to exterior units akin to good telephones. The key parameter that stops development of really miniaturised pumps is the dimensions of the insulin cartridge. Therefore, there’s a robust unmet vital want for concentrated insulin that will allow maintaining a given quantity of insulin in as small a quantity as doable. The product developed by Arecor in partnership with JDRF is a vital step towards assembly this want. 

About JDRF

JDRF is the main world group funding sort 1 diabetes (T1D) analysis. Our mission is to speed up life-changing breakthroughs to treatment, stop and deal with T1D and its issues. To accomplish this, JDRF has invested greater than $2 billion in analysis funding since our inception. We are a company constructed on a grassroots mannequin of folks connecting of their native communities, collaborating regionally for effectivity and broader fundraising influence, and uniting on a nationwide stage to pool sources, ardour, and vitality. We collaborate with educational establishments, policymakers, and company and business companions to develop and ship a pipeline of revolutionary therapies to folks residing with T1D. Our employees and volunteers all through the United States and our six worldwide associates are devoted to advocacy, neighborhood engagement and our imaginative and prescient of a world with out T1D. For extra data, please go to or comply with us on Twitter: @JDRF.

About Arecor

Arecor Ltd is a pacesetter in growing superior biopharmaceuticals via the appliance of an revolutionary formulation know-how platform. Arecor is leveraging this platform to develop a portfolio of proprietary merchandise that can allow improved remedies for diabetes by way of the revolutionary reformulation of accepted proteins and peptides.  Arecor’s product portfolio additionally consists of:

  • Stable aqueous glucagon for emergency and synthetic pancreas use,
  • Novel insulin formulations to ship ultra-rapid performing insulin analogs and;
  • Ultra-concentrated fast performing insulin to allow the miniaturisation of units, and
  • A sequence of undisclosed pre-clinical programmes.

In addition, Arecor companions with main pharmaceutical and biotech firms to ship superior reformulations of their proprietary merchandise, which might in any other case not be doable utilizing typical formulation science.


About ArestatTM

Arecor has important expertise and a confirmed monitor file in making use of the ArestatTM formulation know-how platform to ship superior biopharmaceutical product profiles throughout a broad vary of proteins, peptides and vaccines.



For extra data, please contact:

Arecor   Limited


Dr Sarah   Howell, Chief Executive

Tel: +44   (zero) 1223 426 060

Peckwater   PR

Tarquin   Edwards

Tel: +44   (zero) 7879 458 364


For JDRF Media Enquiries, please contact:

Kristy Evans, Manager, Public Relations &   Communications

Tel: (212) 859-7877

(Visited 9 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *